STC-004

Business news, market intelligence, and global industry analysis.

The Latest

Is DLL3 becoming the most strategic biomarker target in neuroendocrine oncology?

realme Buds T310 in Agile White: top true wireless earbuds under ₹2,000

realme Buds T310 review: Are these the best budget ANC earbuds under ₹2,000?

Why support-platform strategy may become a differentiator in schizophrenia treatment markets

Representative image of gold bars and tanker traffic in the Strait of Hormuz, illustrating why gold prices climbed to a one-month high even as the waterway was declared completely open.

What gold’s latest rally says about geopolitical hedging after the Strait of Hormuz reopening

Representative image of Eli Lilly Headquarters in Indianapolis, Indiana: The pharma giant strengthens its neuroscience footprint with a $1B acquisition of SiteOne Therapeutics, advancing non-opioid pain innovation.

How Eli Lilly’s $1bn SiteOne deal strengthens its bid to lead in non-opioid pain therapies

Eli Lilly to acquire SiteOne Therapeutics for up to $1B, betting on STC-004 to redefine non-opioid pain treatment. Read why investors and analysts are watching.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

May 28, 2025